A patient-level Markov microsimulation applied SOLOIST-WHF trial effects to patients with type 2 diabetes starting sotagliflozin around discharge for worsening heart failure. Over a lifetime horizon, from a US payer perspective, the drug added 0.39 quality-adjusted life-years at $75,510 per QALY gained. That ratio was $71,135 per QALY in preserved ejection fraction and $87,635 in reduced ejection fraction.
Why it is interesting: The ratio is lower in preserved than in reduced ejection fraction, and rests on the assumed drug price.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.